Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration
British Journal of Pharmacology · 2026
DOI: 10.1111/bph.70387 ↗At a glance
Journal article in British Journal of Pharmacology, 2026. Written by Radka Kočvarová and 12 co-authors. Institution: Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jeru…. Major MEDLINE topics: Cannabidiol, Cannabinoids, Lysosomes, Fatty Liver. Cited 1 times so far (Crossref); 115 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministry of Innovation, Science & Technology, Israel Science Foundation, CiiTECH Ltd.
Abstract (original language)
Background and Purpose Cannabidiol (CBD) and cannabigerol (CBG) are non‐psychoactive phytocannabinoids with emerging therapeutic potential in metabolic dysfunction‐associated steatotic liver disease (MASLD). However, the molecular mechanisms underlying their beneficial effects remain incompletely understood. In this study, we assessed the metabolomic and lipidomic impact of CBD and CBG in a mouse model of diet‐induced obesity and MASLD. Experimental Approach Male C57Bl/6 mice fed on a high‐fat diet for 14 weeks were treated for 4 weeks with daily intraperitoneal CBD, CBG or vehicle. Assessments included body composition, indirect calorimetry, glucose tolerance, serum biochemistry and VLDL‐triglyceride profiling. Hepatic mechanisms were examined by metabolomics, lipidomics, creatine kinase activity, cathepsin activity‐based probes and gene/protein expression, with a choline‐deficient diet cohort to test phospholipid‐dependence of CBG. Key Results CBD or CBG treatment improved glycaemic control, reduced hepatic triglycerides and normalised serum lipids, without affecting energy expenditure. Metabolomics revealed increased hepatic phosphocreatine and creatine with enhanced creatine kinase activity, indicating phosphocreatine‐based energy buffering independent of fatty acid oxidation changes. Lipidomics showed reduced triglycerides and ceramides, with increased phospholipids and lysobisphosphatidic acids, correlating with restored hepatic cathepsin activity and improved lysosomal lipid degradation. CBG was ineffective in choline‐deficient MASLD, indicating phospholipid pathway dependence. Conclusions and Implications These findings identify a novel, endocannabinoid system‐independent mechanism by which CBD and CBG enhance hepatic energy buffering and lysosomal function, contributing to improved liver lipid handling and supporting phytocannabinoids as promising MASLD therapeutics.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Obesity and Metabolism Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Laura and Isaac Perlmutter Metabolomics Center, B. Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- Department of Microbiology and Molecular Genetics, Institute for Medical Research Israel-Canada, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Info-CORE, Bioinformatics Unit of the I-CORE, The Hebrew University of Jerusalem, Jerusalem, Israel.
- Protease Research Laboratory, The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, Jerusalem, Israel.
ORCID profiles: Ifat Abramovich, Saveliy Kirillov, Alina Nemirovski, Saja Baraghithy, Inbar Plaschkes, Emmanuelle Merquiol, Alexander Rouvinski, Galia Blum, Liad Hinden, Joseph Tam
Funding
- Ministry of Innovation, Science & Technology
- Israel Science Foundation
- CiiTECH Ltd
Cite
APA
Kočvarová, R., Azar, S., Agranovich, B., Abramovich, I., Kirillov, S., Nemirovski, A., Baraghithy, S., Plaschkes, I., Merquiol, E., Rouvinski, A., Blum, G., Hinden, L., & Tam, J. (2026). Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration. British Journal of Pharmacology. https://doi.org/10.1111/bph.70387
Vancouver
Kočvarová R, Azar S, Agranovich B, Abramovich I, Kirillov S, Nemirovski A, et al. Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration. British Journal of Pharmacology. 2026. doi:10.1111/bph.70387
BibTeX
@article{Kovarov2026,
author = {Kočvarová, Radka and Azar, Shahar and Agranovich, Bella and Abramovich, Ifat and Kirillov, Saveliy and Nemirovski, Alina and Baraghithy, Saja and Plaschkes, Inbar and Merquiol, Emmanuelle and Rouvinski, Alexander and Blum, Galia and Hinden, Liad and Tam, Joseph},
title = {Cannabidiol and cannabigerol ameliorate steatotic liver disease via phosphocreatine buffering and lysosomal restoration},
journal = {British Journal of Pharmacology},
year = {2026},
doi = {10.1111/bph.70387}
}
EUVIMED